Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$503.89 USD
+3.77 (0.75%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $504.14 +0.25 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$503.89 USD
+3.77 (0.75%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $504.14 +0.25 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
Zacks News
Boston Scientific (BSX) Banks on Global Expansion, Innovation
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio
by Zacks Equity Research
GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.
Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software
by Zacks Equity Research
Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
by Zacks Equity Research
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
by Zacks Equity Research
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 1.30% and 0.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Expands Its Facility Capabilities in Germany
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
Stryker (SYK) Completes Artelon's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
by Zacks Equity Research
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Patterson Companies (PDCO) Aims to Streamline Patient Experience
by Zacks Equity Research
Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.
3 Reasons Why You Should Hold McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson's (MCK) robust Biologics business raises optimism about the stock.
What Analyst Projections for Key Metrics Reveal About Elevance Health (ELV) Q2 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
by Zacks Equity Research
Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
by Zacks Equity Research
Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tame Volatility with These 3 Low Beta Stocks
by Derek Lewis
Low beta stocks can offer stabilization when combined with high-beta stocks, providing a more balanced risk profile.
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
by Zacks Equity Research
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.